Senzime AB (publ) (SEZI.ST) Stock Price
Senzime AB (publ) Price
Senzime AB (publ) (SEZI.ST) Stock | ISIN SE0002478776 | WKN A0X93V. Revenue is 179.52 M SEK. Net income is -60 M SEK. Senzime AB (publ) operates in the Health sector.
Senzime AB (publ) stock price
Details
Stock Price
ⓘHow to Read This Chart
This chart tracks the historical stock price of Senzime AB (publ) over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.
Total Return vs. Price Return
The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.
Intraday Price Data
When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Senzime AB (publ) stock reacts to market openings, earnings releases, or breaking news throughout the trading session.
What to Look For
Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Senzime AB (publ)'s price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.
| Date | Senzime AB (publ) Price |
|---|
Senzime AB (publ) Revenue, EBIT, Net Income
3 Years
5 Years
10 Years
25 Years
Max
Details
Senzime AB (publ) Income Statement, Balance Sheet, Cash Flow Statement
| REVENUE (M SEK) |
|---|
| REVENUE GROWTH (%) |
| GROSS MARGIN (%) |
| GROSS INCOME (M SEK) |
| NET INCOME (M SEK) |
| NET INCOME GROWTH (%) |
| SHARES (M) |
| DOCUMENTS |
Details
Income Statement Key Figures
ⓘRevenue and Revenue Growth
Revenue is the starting point of every income statement — it measures the total sales Senzime AB (publ) generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.
Gross Margin
Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Senzime AB (publ) retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Senzime AB (publ)'s gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.
EBIT and EBIT Margin
EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.
Net Income and Earnings Per Share (EPS)
Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.
Shares Outstanding
The total number of shares Senzime AB (publ) has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.
Analyst Estimates
The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Senzime AB (publ)'s historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.
Senzime AB (publ) stock margins
3 Years
5 Years
10 Years
25 Years
Max
Details
Senzime AB (publ) Stock Revenue, EBIT, Earnings per Share
3 Years
5 Years
10 Years
25 Years
Max
Details
Senzime AB (publ) business model & stock analysis
Senzime AB (publ) SWOT Analysis
Strengths
Senzime AB (publ) prides itself on delivering high-quality products and innovative technology. The company's commitment to research and development enables them to offer advanced medical devices and solutions that meet the needs of healthcare professionals and patients.
Senzime AB (publ) has successfully established a strong market presence in the medical device industry. The company's brand reputation, customer trust, and global distribution network contribute to its competitive advantage. This solid market position helps attract new customers and retain existing ones.
Weaknesses
Senzime AB (publ) relies heavily on specific market segments for its revenue generation. Any downturn or disruption in these markets could potentially impact the company's financial performance. Actively diversifying into new healthcare sectors could help mitigate this weakness.
As a relatively small company, Senzime AB (publ) may face resource constraints in terms of capital, marketing, and distribution capabilities. This could limit the company's ability to compete with larger players in the industry. However, the company's agility and focus on niche markets can also be seen as an advantage.
Opportunities
The global medical device market is experiencing significant growth due to increasing healthcare expenditure, aging population, and advancements in technology. Senzime AB (publ) is well-positioned to capitalize on this opportunity by expanding its product portfolio and entering new markets.
Forming strategic partnerships and collaborations with leading technology companies or healthcare institutions can provide Senzime AB (publ) with access to new technologies, expertise, and resources. This can facilitate product development and enhance the company's competitive advantage.
Threats
The medical device industry is highly competitive, with numerous established players and new entrants. Senzime AB (publ) faces the risk of competitors offering similar products, effectively capturing market share, or engaging in aggressive pricing strategies. Continuous innovation and differentiation are crucial to mitigate this threat.
Operating in the medical device sector requires strict adherence to regulatory standards and compliance with various healthcare regulations. Changes in regulations or failure to comply might lead to delayed product approvals, increased costs, or reputational damage. Senzime AB (publ) must stay updated and ensure compliance to minimize such risks.
Senzime AB (publ) Eulerpool Fair Value
Details
Fair Value Estimate
ⓘWhat Is Fair Value?
Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.
Earnings-Based Fair Value
Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.
Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021
Revenue-Based Fair Value
Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"
Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021
Dividend-Based Fair Value
Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.
Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021
How to Use This Chart
When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.
Senzime AB (publ) historical P/E ratio, EBIT multiple, and P/S ratio
Senzime AB (publ) annual returns
Details
Annual Return
ⓘWhat This Chart Shows
This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.
Price Return
Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.
Dividend Return
Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.
What to Look For
Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.
Senzime AB (publ) shares outstanding
3 Years
5 Years
10 Years
25 Years
Max
Details
Senzime AB (publ) Earnings Estimates
Senzime AB (publ) Earnings Estimates
| Date | EPS estimate | Revenue Estimate | Quarterly report |
|---|---|---|---|
| 5/3/2024 | -0.31SEK | 16.32 MSEK | 2024 Q1 |
| 1/30/2024 | -0.31SEK | 13.26 MSEK | 2023 Q4 |
| 2/14/2020 | -1.62SEK | 3.55 MSEK | 2019 Q4 |
| 11/8/2019 | 0SEK | 3.55 MSEK | 2019 Q3 |
| 8/22/2019 | 0SEK | 2.03 MSEK | 2019 Q2 |
| 5/8/2019 | -SEK | 2.03 MSEK | 2019 Q1 |
EESG©
Eulerpool ESG Scorecard© for the Senzime AB (publ) stock
EEnvironment
20
Environment
SSocial
20
Social
GGovernance (Corporate Governance)
4
Governance (Corporate Governance)
The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.
Senzime AB (publ) shareholder structure
| % | Name |
|---|---|
17.60856% | |
10.79111% | |
8.07728% | |
5.56681% | |
5.40795% | |
4.75132% | |
4.20982% | |
4.13414% | |
3.25019% | |
3.07131% |
Senzime AB (publ) Executives and Management Board
Mr. Philip Siberg
(52)Chief Executive Officer · since 2015
Dr. Sorin Brull
(69)Executive Director, Chief Medical Officer · since 2016
Mr. Per Wold-Olsen
(77)Independent Chairman of the Board
Mr. Adam Dahlberg
(52)Deputy Chairman of the Board · since 2000
Mr. Lars Axelson
(64)Director
Senzime AB (publ) Supply Chain
Frequently asked questions about Senzime AB (publ)
The business model of Senzime AB (publ) is focused on the development and commercialization of medical technology products for monitoring patients during surgeries. Senzime offers innovative solutions that enable healthcare professionals to accurately assess and manage patients' physiological responses in real-time, providing valuable data for improved patient care and outcomes. Senzime's flagship product is the TetraGraph, a neuromuscular monitoring system that helps in measuring the patient's muscle function and depth of blockade during anesthesia. By delivering advanced monitoring solutions, Senzime aims to enhance patient safety and optimize anesthesia management in healthcare settings.
Senzime AB (publ) stock
Senzime AB (publ) Peer Group
Senzime AB (publ) Ticker
Senzime AB (publ) FIGI
All fundamentals and in-depth analysis of Senzime AB (publ)
Our stock analysis for Senzime AB (publ) Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Senzime AB (publ) Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.